Dapagliflozin treatment and cardiovascular outcome in RBP4/TTRVal30Met (transthyretin cardiac amyloidosis) mice

Dapagliflozin treatment and cardiovascular outcome in RBP4/TTRVal30Met (transthyretin cardiac amyloidosis) mice

Abstract Aims Whether sodium‐glucose co‐transporter 2 inhibitors are effective for heart failure caused by ATTR‐CA (transthyretin cardiac amyloidosis) remains uncertain. The aim of this study is to investigate the cardiovascular prognosis in ATTR‐CA mice model with dapagliflozin treatment. Methods a...

Full description

Bibliographic Details
Main Authors:	Zonglin Li, Fang Lv, Xin Wen, Chengcheng Guo, Li Li, Xiaoling Cai, Chu Lin, Mengqing Zhang, Wenjia Yang, Linong Ji
Format:	Article
Language:	English
Published:	Wiley 2024-02-01
Series:	ESC Heart Failure
Subjects:	ATTR Cardiovascular prognosis Dapagliflozin Heart failure Transthyretin cardiac amyloidosis
Online Access:	https://doi.org/10.1002/ehf2.14567

Similar Items

Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis
by: Hiroaki Matsushita, et al.
Published: (2022-06-01)

Specific therapeutic options for transthyretin amyloidosis
by: Zoltán Pozsonyi
Published: (2024-12-01)

Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report
by: Hiroyuki Yamamoto, et al.
Published: (2018-12-01)

Phenotypic heterogeneity and diagnostic features of transthyretin amyloidosis with polyneuropathy
by: S. S. Nikitin, et al.
Published: (2021-12-01)

Advances in the treatment of hereditary transthyretin amyloidosis: A review
by: Morie A. Gertz, et al.
Published: (2019-09-01)

The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement
by: Chafic Karam, et al.
Published: (2024-11-01)

A Clinical Case of the Hereditary Transthyretin Amyloidosis
by: E. V. Reznik, et al.
Published: (2021-05-01)

SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin
by: Stephan Dobner, et al.
Published: (2023-02-01)

The application of biomarkers in hereditary transthyretin amyloidosis – an ongoing research project on bulgarian patients
by: Z. Pavlova, et al.
Published: (2024-04-01)

Oligomerization Profile of Human Transthyretin Variants with Distinct Amyloidogenicity
by: Ana Frangolho, et al.
Published: (2020-12-01)

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
by: Dulce Brito (Chair), et al.
Published: (2023-10-01)

Best Practices in Nuclear Imaging for the Diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in KSA: The Eagle Eyes of Local Experts
by: Abdullah Alqarni, et al.
Published: (2024-01-01)

Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner
by: Morie Gertz, et al.
Published: (2020-09-01)

Neuromuscular manifestations of wild type transthyretin amyloidosis: a review and single center’s experience
by: Sasha A. Živković, et al.
Published: (2024-02-01)

Clinical case of hereditary transthyretin amyloidosis
by: N. Spasova, et al.
Published: (2024-12-01)

Diagnostic algorithm in transthyretin amyloidosis with cardiomyopathy
by: Mariana Gospodinova, et al.
Published: (2020-07-01)

Systemic amyloidosis in a patient with acute heart failure
by: E. V. Shekhovtsova, et al.
Published: (2024-08-01)

Late-Onset Hereditary Transthyretin Amyloidosis Val30Met in an Elderly Person in a Non-Endemic Area
by: Wang S, et al.
Published: (2022-06-01)

Biochemical and biophysical properties of a rare TTRA81V mutation causing mild transthyretin amyloid cardiomyopathy
by: Qiuyan Sha, et al.
Published: (2024-02-01)

Suspecting and diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM) in India: An Indian expert consensusKey recommendations by panel on patient journey and red flagsKey recommendations by the panel on tools for diagnosisKey recommendations by the panel on comparison of global ATTR-CM guidelines
by: Jagdish Chander Mohan, et al.
Published: (2022-11-01)

Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real‐World Data
by: Maximilian Leo Müller, et al.
Published: (2024-07-01)

Transthyretin Amyloidosis Therapies: Guiding the Future
by: Alejandra González-Duarte
Published: (2021-01-01)

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
by: Faruk Uğur Doğan, et al.
Published: (2019-03-01)

Diagnostic and Prognostic Values of Cardiopulmonary Exercise Testing in Cardiac Amyloidosis
by: Rishika Banydeen, et al.
Published: (2022-06-01)

Clinical and genetic profiles of patients with hereditary and wild-type transthyretin amyloidosis: the Transthyretin Cardiac Amyloidosis Registry in the state of São Paulo, Brazil (REACT-SP)
by: Fábio Fernandes, et al.
Published: (2024-07-01)

Health‐related quality of life among transthyretin amyloid cardiomyopathy patients
by: Per Eldhagen, et al.
Published: (2023-06-01)

Hereditary systemic transthyretin amyloidosis: a clinical case and an opinion on the problem
by: A. S. Draganova, et al.
Published: (2019-07-01)

Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis
by: Hiroki Yamaguchi, et al.
Published: (2022-03-01)

Cardiac amyloidosis is not a single disease: a multiparametric comparison between the light chain and transthyretin forms
by: Gabriela Neculae, et al.
Published: (2024-10-01)

NON-VAL30MET-TRANSTHYRETIN AMYLOID CARDIOMYOPATHY. LITERATURE REVIEW AND CLINICAL CASE
by: A. Ya. Gudkova, et al.
Published: (2018-03-01)

Hereditary transthyretin amyloidosis
by: T. A. Adyan, et al.
Published: (2020-01-01)

Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis
by: Richard K. Cheng, et al.
Published: (2021-12-01)

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy
by: Nicholas Streicher, et al.
Published: (2024-03-01)

A Comparative Study of the Electroneurographic Findings in Amyloidotic Polyneuropathy in Patients with Light-Chain Amyloidosis and Glu54Gln Transthyretin Amyloidosis
by: Mirela Drăghici, et al.
Published: (2024-12-01)

Oxidative Stress in Transthyretin-Mediated Amyloidosis: An Exploratory Study
by: Marco Fiore, et al.
Published: (2024-08-01)

Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey
by: Juan González-Moreno, et al.
Published: (2023-12-01)

The Transthyretin/Oleuropein Aglycone Complex: A New Tool against TTR Amyloidosis
by: Francesco Bemporad, et al.
Published: (2022-02-01)

A clinical case of transthyretin amyloidosis with manifestations of seronegative arthritis
by: V. A. Mareeva, et al.
Published: (2024-02-01)

Myocardial perfusion imaging-derived left ventricular strain: Regional abnormalities associated with transthyretin cardiac amyloidosis
by: Steven Lewis, et al.
Published: (2024-04-01)

Coexistence of Light Chain and Transthyretin Cardiac Amyloidosis
by: Abhishek Gami, MD, et al.
Published: (2024-04-01)